Irak Inhibitors and Method for Making and Using
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 62/413,217, filed Oct 26, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,370,367 | Irak Inhibitors and Method for Making and Using In force · High confidence UsedRemaining | Rigel Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,941,140 | Irak Inhibitors and Method for Making and Using In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,492,349 | Irak Inhibitors and Method for Making and Using In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,993,594 | Irak Inhibitors and Method for Making and Using In force · High confidence | Rigel Pharmaceuticals, Inc. | In force | High confidence |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.